Abstract
Introduction
Biotechnology is the utilization of biological systems for scientific discoveries and production of goods and services that improve the human environment. Biopharming involves large scale production of recombinant proteins by using transgenic animals. In a transgenic animal, foreign DNA has been incorporated so that their DNA is altered producing proteins that normally they would not produce. This concept was first developed by Briggs and King (1952) and later Gordon and Ruddle (1981) produced first transgenic mouse by DNA microinjection method. Since then there has been rapid development in the use of genetically engineered animals and constant efforts are made to improve the efficiency of generating transgenic livestock (Hyttinen et al., 1994; Kopchick et al., 1996) .
How to Generate Transgenic Animals?
Several methods have been tried for transgenic animal production through the years (Irvine, 1991; Wheeler, 2003; Zaman, 2013) . All these protocols include two fundamental aspects of transgenic technology: the generation of recombinant DNA suitable for transgenic expression and the techniques employed to introduce it into animals.
The steps for production of 'transgenic animals' include - for its exceptional mechanical strength has been produced in milk (Williams, 2003) . Urine can be used to collect recombinant proteins (e.g. gonadotropins) for pharmaceutical use (Meade and Ziomek, 1998) . The human growth hormone gene can be expressed specifically in urothelium of mouse and collected through urine. Seminal plasma can be used to collect human growth hormone from transgenic mice. Similarly, transgenic bird can be developed which will secrete recombinant proteins through egg white.
Which Recombinant Proteins to Be Produced?
The gene coding for recombinant proteins should be selected on the basis of scientific, economic and social realities (Houdebine, . Tissue specific expression of recombinant proteins is more advantageous than generalized expression as it will be easier to regulate the gene expression in a tissue specific manner (Larrick and Thomas, 2001 ). For example, promoter elements derived from the casein and whey families have been used to direct expression and secretion of the recombinant proteins in the milk of cows, sheep and goats (Rudolph, 1999) .
Another important issue in production of recombinant proteins is whether the foreign protein will have any effect on physiology of transgenic animal (Palmer et al., 2003; Faizi, 2013) . Some pharmaceutical proteins exhibit adverse effect in transgenic animals, though their number is very less.
Limitations of Biopharming
Though, the transgenic procedure sounds very promising, but very expensive, and still has a low rate of success (Houdebine, 1994; Brink et al., 2000) , especially for larger farm animals. The transgenic organisms producing recombinant proteins show some unexpected results like impaired mammary gland development, agalactia, gastric ulcer, arthritis, infertility and premature death (Ward et 
